Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation

Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
OR 2.11 [0.18, 25.35]
2 studies · 84 participants
Very low